Birchview Capital LP maintained its position in Xencor, Inc. (NASDAQ:XNCR) during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 12,300 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Xencor accounts for approximately 0.2% of Birchview Capital LP’s holdings, making the stock its 25th largest position. Birchview Capital LP’s holdings in Xencor were worth $324,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. DIAM Co. Ltd. acquired a new position in Xencor during the third quarter worth approximately $154,000. Capital Fund Management S.A. acquired a new position in Xencor during the third quarter worth approximately $220,000. Zacks Investment Management acquired a new position in Xencor during the third quarter worth approximately $249,000. Matarin Capital Management LLC acquired a new position in Xencor during the third quarter worth approximately $329,000. Finally, Virginia Retirement Systems ET AL acquired a new position in Xencor during the third quarter worth approximately $353,000. Institutional investors own 63.40% of the company’s stock.
Shares of Xencor, Inc. (NASDAQ:XNCR) traded up 0.04% during midday trading on Friday, reaching $23.75. 143,298 shares of the company traded hands. Xencor, Inc. has a 12-month low of $10.41 and a 12-month high of $29.38. The company has a 50-day moving average of $24.41 and a 200 day moving average of $23.31. The firm has a market capitalization of $977.03 million, a PE ratio of 24.33 and a beta of 2.21.
A number of equities analysts have recently commented on XNCR shares. Zacks Investment Research upgraded shares of Xencor from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Saturday, November 5th. Leerink Swann restated a “buy” rating and set a $26.00 price objective on shares of Xencor in a research note on Thursday, November 3rd. Canaccord Genuity set a $32.00 price objective on shares of Xencor and gave the stock a “buy” rating in a research note on Monday, November 28th. Finally, TheStreet upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research note on Friday, December 2nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Xencor has an average rating of “Buy” and a consensus price target of $28.33.
In other Xencor news, major shareholder John S. Stafford III sold 63,061 shares of Xencor stock in a transaction on Tuesday, December 6th. The shares were sold at an average price of $27.71, for a total value of $1,747,420.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.03% of the company’s stock.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/xencor-inc-xncr-stake-maintained-by-birchview-capital-lp/1655022.html
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.